Description

The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

Summary

GBI Research, the leading business intelligence provider, has released its latest research “The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis.” The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global HIV therapeutics market. The report analyzes the markets for HIV therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2015 for the key geographies. Further, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global market.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

Scope

The scope of this report includes:
- Annualized market data for the HIV therapeutics market from 2000 to 2008, forecast forward to 2015
- Analysis of the HIV therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan
- Market characterization of the HIV therapeutics market including market size, annual cost of therapy, sales volume and treatment usage patterns
- Key drivers and barriers that have a significant impact on the market
- Coverage of pipeline molecules in various phases of drug development
- Competitive benchmarking of leading companies. The key companies studied in this report are Gilead Sciences Inc, GlaxoSmithKline, Bristol-Myers Squibb, Abbott Laboratories, Merck & Co and Pfizer Inc
- Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global HIV therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to
- Align product portfolio to the markets with high growth potential
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety
- Develop key strategic initiatives by understanding key focus areas of leading companies
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps

Companies Mentioned

Gilead
GlaxoSmithKline (GSK)
Bristol-Myers Squibb (BMS)
Abbott Laboratories
Merck
Pfizer

Table Of Contents

List of Tables

1.1 List of Tables
Table 1: HIV Therapeutics Market, Global, Revenue ($m), 2000-2008 14
Table 2: HIV Market, Global, Revenue ($m), 2008-2015 14
Table 3: HIV Therapeutics Market, Global, Revenue Segmentation ($m), 2000-2008 15
Table 4: HIV Therapeutics Market, Global, Revenue Segmentation ($m), 2008-2015 15
Table 5: HIV Therapeutics Market, Global, Average Cost of Therapy ($), 2000-2008 16
Table 6: HIV Therapeutics Market, Global, Average Cost of Therapy ($), 2008-2015 16
Table 7: HIV Therapeutics Market, Global, Volume (million), 2000-2008 17
Table 8: HIV Therapeutics Market, Global, Volume (million), 2008-2015 17
Table 9: HIV Therapeutics Market, Global, Diseased Population, 2000-2008 19
Table 10: HIV Therapeutics Market, Global, Diseased Population, 2008-2015 19
Table 11: HIV Therapeutics Market, Global, Treatment Seeking Population, 2000-2008 20
Table 12: HIV Therapeutics Market, Global, Treatment Seeking Population, 2008-2015 20
Table 13: HIV Therapeutics Market, Global, Diagnosis Population, 2000-2008 21
Table 14: HIV Therapeutics Market, Global, Diagnosis Population, 2008-2015 21
Table 15: HIV Therapeutics Market, Global, Prescription Population, 2000-2008 22
Table 16: HIV Therapeutics Market, Global, Prescription Population, 2008-2015 22
Table 17: HIV Therapeutics Market, Global, Usage Patterns, 2000-2008 24
Table 18: HIV Therapeutics Market, Global, Usage Patterns, 2008-2015 24
Table 19: HIV Therapeutics Market, Global, Market Drivers, 2008 27
Table 20: HIV Therapeutics Market, Global, Market Restraints, 2008 30
Table 21: HIV Therapeutics Market, Global, Key Drug Going Off Patent, 2008-15 30
Table 22: HIV Therapeutics Market, US, Revenues ($m), 2000-2008 36
Table 23: HIV Therapeutics Market, US, Revenue ($m), 2008-2015 37
Table 24: HIV Therapeutics Market, US, Average Cost of Therapy ($), 2000-2008 37
Table 25: HIV Therapeutics Market, US, Average Cost of Therapy ($), 2008-2015 38
Table 26: HIV Therapeutics Market, US, Volume (million), 2000-2008 38
Table 27: HIV Therapeutics Market, US, Volume (million), 2008-2015 39
Table 28: HIV Therapeutics Market, US, Diseased Population, 2000-2008 40
Table 29: HIV Therapeutics Market, US, Diseased Population, 2008-2015 40
Table 30: HIV Therapeutics Market, US, Treatment Seeking Population, 2000-2008 41
Table 31: HIV Therapeutics Market, US, Treatment Seeking Population, 2008-2015 41
Table 32: HIV Therapeutics Market, US, Diagnosis Population, 2000-2008 42
Table 33: HIV Therapeutics Market, US, Diagnosis Population, 2008-2015 42
Table 34: HIV Therapeutics Market, US, Prescription Population, 2000-2008 43
Table 35: HIV Therapeutics Market, US, Prescription Population, 2008-2015 43
Table 36: HIV Therapeutics Market, US, Usage Patterns, 2000-2008 44
Table 37: HIV Therapeutics Market, US, Usage Patterns, 2008-2015 45
Table 38: HIV Therapeutics Market, Europe, Revenues ($m), 2000-2008 47
Table 39: HIV Therapeutics Market, Europe, Revenue ($m), 2008-2015 47
Table 40: HIV Therapeutics Market, Europe, Average Cost of Treatment, 2000-2008 48
Table 41: HIV Therapeutics Market, Europe, Average Cost of Treatment, 2008-2015 48
Table 42: HIV Therapeutics Market, Europe, Volume (million), 2000-2008 49
Table 43: HIV Therapeutics Market, Europe, Volume (million), 2008-2015 49
Table 44: HIV Therapeutics Market, Europe, Diseased Population, 2000-2008 50
Table 45: HIV Therapeutics Market, Europe, Diseased Population, 2008-2015 50
Table 46: HIV Therapeutics Market, Europe, Treatment Seeking Population, 2000-2008 51
Table 47: HIV Therapeutics Market, Europe, Treatment Seeking Population, 2008-2015 51
Table 48: HIV Therapeutics Market, Europe, Diagnosis Population, 2000-2008 52
Table 49: HIV Therapeutics Market, Europe, Diagnosis Population, 2008-2015 53
Table 50: HIV Therapeutics Market, Europe, Prescription Population, 2000-2008 53
Table 51: HIV Therapeutics Market, Europe, Prescription Population, 2008-2015 54
Table 52: HIV Therapeutics Market, Europe, Usage Patterns, 2000-2008 55
Table 53: HIV Therapeutics Market, Europe, Usage Patterns, 2008-2015 55
Table 54: HIV Therapeutics Market, Japan, Revenue ($m), 2000-2008 57
Table 55: HIV Therapeutics Market, Japan, Revenue ($m), 2008-2015 57
Table 56: HIV Therapeutics Market, Japan, Average Cost of Therapy ($), 2000-2008 58
Table 57: HIV Therapeutics Market, Japan, Average Cost of Therapy ($), 2008-2015 58
Table 58: HIV Therapeutics Market, Japan, Volume (million), 2000-2008 59
Table 59: HIV Therapeutics Market, Japan, Volume (million), 2008-2015 59
Table 60: HIV Therapeutics Market, Japan, Diseased Population, 2000-2008 60
Table 61: HIV Therapeutics Market, Japan, Diseased Population, 2008-2015 60
Table 62: HIV Therapeutics Market, Japan, Treatment Seeking Population, 2000-2008 61
Table 63: HIV Therapeutics Market, Japan, Treatment Seeking Population, 2008-2015 61
Table 64: HIV Therapeutics Market, Japan, Diagnosis Population, 2000-2008 62
Table 65: HIV Therapeutics Market, Japan, Diagnosis Population, 2008-2015 62
Table 66: HIV Therapeutics Market, Japan, Prescription Population, 2000-2008 63
Table 67: HIV Therapeutics Market, Japan, Prescription Population, 2008-2015 63
Table 68: HIV Therapeutics Market, Japan, Usage Patterns, 2000-2008 64
Table 69: HIV Therapeutics Market, Japan, Usage Patterns, 2008-2015 64
Table 70: HIV Market, Global, Different Classes of Drugs 66
Table 71: HIV Therapeutics Market, Global, Pipeline Analysis, Phase I, 2008 70
Table 72: HIV Therapeutics Market, Global, Pipeline Analysis, Phase II, 2008 71
Table 73: HIV Therapeutics Market, Global, Pipeline Analysis, Phase III, 2008 73
Table 74: HIV Therapeutics Market, Global, Major Drugs and Manufacturers, 2008 79
Table 75: HIV Therapeutics Market, Global, Benchmarking Analysis for Top Three Companies, 2008 81
Table 76: HIV Therapeutics Market, Global, Licensing Agreements for Drugs in the Preclinical Stage, 2008 92
Table 77: HIV Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase II, 2008 93
Table 78: HIV Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase III, 2008 93
Table 79: HIV Therapeutics Market, Global, Licensing Agreements for Approved Drugs, 2008 94

List of Figures

1.2 List of Figures
Figure 1: HIV Therapeutics Market, Global, Market Overview, 2008 13
Figure 2: HIV Therapeutics Market, Global, Revenue ($m), 2000-2015 14
Figure 3: HIV Therapeutics Market, Global, Average Cost of Therapy ($), 2000-2015 16
Figure 4: HIV Therapeutics Market, Global, Volume (million), 2000-2015 17
Figure 5: HIV Therapeutics Market, Global, Diseased Population, 2000-2015 18
Figure 6: HIV Therapeutics Market, Global, Treatment Seeking Population, 2000-2015 19
Figure 7: HIV Therapeutics Market, Global, Diagnosis Population, 2000-2015 21
Figure 8: HIV Therapeutics Market, Global, Prescription Population, 2000-2015 22
Figure 9: HIV Therapeutics Market, Global, Usage Patterns, 2000-2015 23
Figure 10: HIV Therapeutics Market, Global, Geographical Distribution of Revenues ($m),
2000-2015 25
Figure 11: HIV Therapeutics Market, Global, Geographical Outlook, 2008 26
Figure 12: HIV Therapeutics Market, Global, Market Indicators, 2008 26
Figure 13: HIV Therapeutics Market, Global, Key Market Events, 2008-2015 32
Figure 14: HIV Therapeutics Market, US, Revenue ($m), 2000-2015 36
Figure 15: HIV Therapeutics Market, US, Average Cost of Therapy ($), 2000-2015 37
Figure 16: HIV Therapeutics Market, US, Volume (million), 2000-2015 38
Figure 17: HIV Therapeutics Market, US, Diseased Population, 2000-2015 39
Figure 18: HIV Therapeutics Market, US, Treatment Seeking Population, 2000-2015 40
Figure 19: HIV Therapeutics Market, US, Diagnosis Population, 2000-2015 41
Figure 20: HIV Therapeutics Market, US, Prescription Population, 2000-2015 43
Figure 21: HIV Therapeutics Market, US, Usage Patterns, 2000-2015 44
Figure 22: HIV Therapeutics Market, Europe, Revenue ($m), 2000-2015 47
Figure 23: HIV Therapeutics Market, Europe, Average Cost of Treatment ($), 2000-2015 48
Figure 24: HIV Therapeutics Market, Europe, Volume (million), 2000-2015 49
Figure 25: HIV Therapeutics Market, Europe, Diseased Population, 2000-2015 50
Figure 26: HIV Therapeutics Market, Europe, Treatment Seeking Population, 2000-2015 51
Figure 27: HIV Therapeutics Market, Europe, Diagnosis Population, 2000-2015 52
Figure 28: HIV Therapeutics Market, Europe, Prescription Population, 2000-2015 53
Figure 29: HIV Therapeutics Market, Europe, Usage Patterns, 2000-2015 54
Figure 30: HIV Therapeutics Market, Japan, Revenue ($m), 2000-2015 56
Figure 31: HIV Therapeutics Market, Japan, Average Cost of Therapy ($), 2000-2015 57
Figure 32: HIV Therapeutics Market, Japan, Volume (million), 2000-2015 58
Figure 33: HIV Therapeutics Market, Japan, Diseased Population, 2000-2015 59
Figure 34: HIV Therapeutics Market, Japan, Treatment Seeking Population, 2000-2015 60
Figure 35: HIV Therapeutics Market, Japan, Diagnosis Population, 2000-2015 61
Figure 36: HIV Therapeutics Market, Japan, Prescription Population, 2000-2015 62
Figure 37: HIV Therapeutics Market, Japan, Usage Patterns, 2000-2015 63
Figure 38: HIV Therapeutics Market, Global, Analysis of Unmet Needs for Major Drug Class, 2008 67
Figure 39: HIV Therapeutics Market, Global, Pipeline by Phase and Class, 2008 69
Figure 40: HIV Therapeutics Market, Global, Competitive Analysis of Major Manufacturers with Respect to Revenues, 2006-08 75
Figure 41: HIV Therapeutics Market, Global, Competitive Analysis of Top 4 Manufacturers,
2006-08 76
Figure 42: HIV Therapeutics Market, Global, Market Share of Top Manufacturers, 2008 77
Figure 43: HIV Therapeutics Market, Global, Benchmark of Top 10 Brands - 2008 78
Figure 44: HIV Therapeutics Market, Gilead, HIV Revenue as Percentage of Total Revenue, 2009 82
Figure 45: HIV Therapeutics Market, GSK, HIV Revenue as Percentage of Total Revenue, 2009 83
Figure 46: HIV Therapeutics Market, BMS, HIV Revenue as Percentage of Total Revenue, 2009 85
Figure 47: HIV Therapeutics Market, Abbott, HIV Revenue as Percentage of Total Revenue, 2009 86
Figure 48: HIV Therapeutics Market, Merck, HIV Revenue as Percentage of Total Revenue, 2009 87
Figure 49: HIV Therapeutics Market, Global, Deals by Geography and Type, 2008 89
Figure 50: HIV Therapeutics Market, Global, MandA Deals, 2008 90
Figure 51: HIV Therapeutics Market, Global, Major Licensing Agreements By Phase, 2008-09 91
Figure 52: GBI Research Methodology 97
Figure 53: GBI Research Market Forecasting Model 100

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • August 2014
  • by Global Data

PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023 Summary Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented ...

PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • September 2014
  • by Global Data

PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cance ...

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

  • $ 10 995
  • Industry report
  • September 2014
  • by Global Data

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Summary During the forecast period from 2012-2022, the growth of the UC market will be driven largely ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.